Last updated: 2026-11-14 03:50:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
DiaMedica Therapeutics Inc. (DMAC) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $8.79, with a market capitalization of $503.13M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.25 to $11.00. This page covers its latest market performance, valuation, price trends and company information.
$503.13M | |
$9.22 | |
$9.36 | |
$8.19 | |
$9.33 | |
202.11K | |
196.66K | |
-- | |
$11.00 | |
$5.25 | |
-- | |
-- |
DiaMedica Therapeutics Inc. (DMAC) last closed at $8.79 as of 2026-11-14 00:31:00, down 5.36% ($0.50) from the previous close of $9.33.
During the latest regular trading session, DMAC traded between $8.19 and $9.36, with a volume of 202.11K shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, DiaMedica Therapeutics Inc. (DMAC) moved from $10.77 to $8.79, representing a decline of 18.43% ($1.98).
The stock traded between $8.19 and $11.00 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 216.44 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 61.5%
DMAC is currently trading at $8.79, placing it 61.5% of the way from its 52-week low of $5.25 to its 52-week high of $11.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 35 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to DiaMedica Therapeutics Inc. and DMAC stock.
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.21) per share which met the analyst consensus estimate. This is a 23.53 percent decrease over losses of $(0.17) per share from the same period last
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.21) per share which met the analyst consensus estimate. This is a 23.53 percent decrease over losses of $(0.17) per share from the same period last
Eligible investors can buy real shares of DiaMedica Therapeutics Inc. (DMAC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to DMAC, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between DMAC shares and USD.
DMAC Shares to USD
1.00 DMAC shares = 8.785 USD
Calculations are estimates based on the latest available price and are for reference only.
